Evercore ISI raised the firm’s price target on Alexandria Real Estate to $133 from $132 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 results for select REITs. While the healthcare sector is trading at a 22% premium to consensus net asset value, the REIT is trading below its respective long-term averages given concerns relating primarily to the lab/life science market fundamentals, the analyst tells investors in a research note. The Q2-Q4 of 2024 deliveries reflect 96% and 98% leased and leased negotiating thresholds, offering strong visibility into the anticipated associated net operating income contribution to 2024 earnings, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARE:
- Alexandria Real Estate announces long-term 127,382 RSF lease
- Alexandria Real Estate increases quarterly dividend 3c to $1.30 per share
- Alexandria Real Estate Equities, Inc. Declares Cash Dividend of $1.30 per Common Share for 2Q24, an Increase of 3 Cents Over 1Q24, and an Aggregate of $5.08 per Common Share for the 12 Months Ending June 30, 2024, an Increase of 24 Cents, or 5 Percent, Over the 12 Months Ended June 30, 2023
- 3 Best REIT Stocks to Buy in May 2024, as per Analysts
- Alexandria Real Estate Equities’ Strategic Annual Meeting Outcomes
Questions or Comments about the article? Write to editor@tipranks.com